A group of experts who advise the US Food and Drug Administration on its vaccine decisions voted unanimously Thursday to make a broad recommendation about which lineage of the coronavirus should be included in this year’s Covid-19 vaccines,

The FDA picked the LP.8.1 Covid strain for the fall vaccines, fueling concerns that the shots may be limited to only the most at-risk Americans this fall.

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

An FDA advisory committee unanimously recommended Thursday that the next COVID vaccine should be a monovalent one in the JN.1 lineage, although members disagreed slightly about which specific strain should be included.

The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at higher risk of severe disease, but will require vaccine makers to conduct major new clinical trials before approving them for wider use.

The FDA said moving forward, it will adopt a framework requiring proof that a vaccine can generate antibodies in people over the age of 65 years and for all persons above the age of 6 months with

The vaccine eligibility change is a threat to the health of Americans, some experts say, adding that the FDA is not being forthcoming about its research.

New guidelines for COVID vaccine. Prior to the new guidelines, it was recommended that everyone who is 6 months and older get at least one vaccine per year, with those in higher-0

With new testing requirements, it’s not even clear whether new Covid or flu shots can be made available this fall.

Yesterday the Vaccine Integrity Project (VIP), a panel of leading public health and policy experts, published a viewpoint on the Food and Drug Administration's (FDA's) decision this week to issue new, more restrictive, COVID-19 vaccine recommendations via an opinion piece in the New England Journal of Medicine (NEJM).